Test Your Knowledge: Ten Questions about Lung Cancer

This quiz is related to the Perspectives article in the March issue of PLoS Medicine (DOI: 10.1371/journal.pmed.0020075).

Gavin Yamey

Question 1. What proportion of lung cancers are small cell lung cancers?
- About 10%
- About 20%–25%
- About 40%–50%
- About 70%

Question 2. In terms of the number of cancer-related deaths worldwide, where does lung cancer rank?
- First
- Second, after colorectal cancer
- Third, after colorectal cancer and stomach cancer

Question 3. What proportion of cases of lung cancer are caused by smoking?
- About 50%–60%
- About 75%
- About 80%–90%
- About 95%–99%

Question 4. Based on the best-available evidence, which of the following oral supplements has been proven to prevent lung cancer when taken by healthy people?
- Alpha-tocopherol
- Beta-carotene
- Retinol
- None of the above

Question 5. What is the overall five-year survival rate for lung cancer?
- 5%–7%
- 10%–12%
- 16%–18%
- 24%–26%

Question 6. Which of the following best reflects the evidence on population-based screening for lung cancer?
- RTCs have shown that screening with spiral computed tomography (CT) reduces lung cancer mortality
- Screening with frequent chest X rays is associated with reduced lung cancer mortality compared with less frequent screening
- Screening with frequent chest X rays is associated with increased lung cancer mortality compared with less frequent screening

Question 7. Which of the following best reflects the evidence on the value of giving palliative chemotherapy to patients with stage 4 non-small cell lung cancer (the most advanced stage)?
- Palliative chemotherapy improves survival at one year and is associated with improved quality of life
- Although palliative chemotherapy improves survival at one year, its side effects mean that the treatment is associated with impaired quality of life
- Palliative chemotherapy is associated with improved quality of life, but there is no evidence that it prolongs survival

Citation: Yamey G (2005) Test your knowledge: Ten questions about lung cancer. PLoS Med 2(3): e93.

Copyright: © 2005 Gavin Yamey. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Gavin Yamey is a senior editor at PLoS Medicine. E-mail: gyamey@plos.org

DOI: 10.1371/journal.pmed.0020093
Question 8. In people with resectable non-small cell lung cancer, which of the following best reflects the evidence on the value of adjuvant chemotherapy?

- There is no evidence that giving adjuvant chemotherapy prolongs survival compared with surgery alone.
- Several systematic reviews and several RCTs have shown conclusively that adjuvant chemotherapy prolongs survival compared with surgery alone.
- Although the overall evidence is inconclusive, two recent RCTs suggest that adjuvant chemotherapy may confer a survival benefit in resectable stage 1B to stage 3 disease.

Answer 4. None of the above

A Cochrane systematic review examined four randomized controlled trials (RCTs) that compared different supplements against each other, or supplements versus placebo, which involved a total of 109,394 participants. The review found no evidence to support recommending vitamins such as alpha-tocopherol, beta-carotene, or retinol, alone or in combination, to prevent lung cancer [1]. The review found a harmful effect (a statistically significant increased risk of lung cancer incidence and mortality) for beta-carotene and retinol at pharmacological doses in people with risk factors for lung cancer (smoking and/or occupational exposure to asbestos).

References
1. Caraballoslo M, Sacristan M, Serra C, Bonfill X (2002) Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev 2002: CD002141.

Answer 5. 10%–12%

The overall five-year survival rate is 10%–12% [1].

References
1. Bude DC, Pass HI, Glasenstein G (1997) Lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, principles, and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven. pp. 849–959.

Answer 6. Screening with frequent chest X rays is associated with increased lung cancer mortality compared with less frequent screening

A Cochrane systematic review searched for all controlled trials of screening for lung cancer using sputum examinations, chest radiography, or chest CT [1]. Seven trials were included (six randomized controlled studies and one nonrandomized controlled trial) with a total of 245,610 participants. Frequent screening with chest X rays was associated with an 11% relative increase in mortality from lung cancer compared with less frequent screening (relative risk = 1.11; confidence interval, 1.00–1.23). The reviewers found no controlled studies of spiral CT. The National Lung Screening Trial (http://www.nci.nih.gov/nlst)—a very large randomized study of 50,000 participants—is underway in the United States to compare mortality between spiral CT and chest X rays.

References
1. Manser RL, Irving LB, Stone C, Byrnes G, Abramson M, et al. (2004) Screening for lung cancer. Cochrane Database Syst Rev 2004: CD001991.

Answer 7. Palliative chemotherapy improves survival at one year and is associated with improved quality of life

Systematic reviews in people with stage 4 non-small cell lung cancer have found that adding chemotherapy regimens that contain cisplatin to best supportive care increases survival at one year compared with supportive care alone [1]. In one review, for example, median survival was 5.5 months with cisplatin-containing regimens plus supportive care versus four months with supportive care alone [2]. There is also some evidence from RCTs that adding chemotherapy to best supportive care may improve quality of life compared with best supportive care alone [1].

References
1. Neville A (2004) Lung cancer. Clin Evid 2004: 2031–2053.
2. Non-Small Cell Lung Cancer Collaborative Group (2002) Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2002: CD002139.
Answer 8. Although the overall evidence is inconclusive, two recent RCTs suggest that adjuvant chemotherapy may confer a survival benefit in resectable stage 1B to stage 3 disease.

While published systematic reviews and RCTs have failed to clearly show a survival benefit [1,2,3,4,5,6], two newer RCTs that have been presented as abstracts at meetings suggest that adjuvant chemotherapy (third-generation agents plus a platinum drug) may confer a survival benefit for resectable stage 1B-3 disease compared with surgery alone [7,8].

References
1. Goss G, Paszat L, Newman T, Evans WK, Browman G (1998) Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small cell lung cancer. Cancer Prev Control 2: 32–39.
2. Depierre A, Milleron B, Morno-Sibilot D, Chevret S, Quoix E, et al. (2002) Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small-cell lung cancer. J Clin Oncol 20: 247–253.
3. Non-Small Cell Lung Cancer Collaborative Group (2002) Chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev 2002: CD001239.
4. Guangchuan XU, Rong T, Lin P (2000) Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: A randomized study on 70 patients. Chin Med J 113: 617–620.
5. Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, et al. (2003) A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40: 181–186.
6. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, et al. (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343: 1217–1222.
7. Winston TL, Livingston R, Johnson D, Rigas J, Cormier Y, et al. (2004) A prospective randomised trial of adjuvant vinorelbin (VIN) and cisplatin (CIS) in completely resected stage II and II non small cell lung cancer (NSCLC) intergroup JBR.10 [abstract]. Proc Am Soc Clin Oncol 2004: abstract number 7018.
8. Strauss GM, Herndon J, Maddaus MA, Johnson EA, et al. (2004) Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of cancer and leukemia group B (CALGB) protocol 9633 [abstract]. Proc Am Soc Clin Oncol 2004: abstract number 7019.

Answer 9. It confers a small survival benefit.

A Cochrane systematic review identified seven RCTs, involving 987 patients with small cell lung cancer in complete remission, comparing cranial irradiation with no cranial irradiation [1]. Cranial irradiation conferred a small survival benefit (relative risk of death at three years was 0.84 [95%; confidence interval, 0.73 to 0.97], corresponding to a 5.4% increase in survival). The fact that the survival benefit is small reflects the impact of other events not influenced by prophylactic cranial irradiation, such as metastases outside the brain or thoracic relapse [2,3].

References
1. Prophylactic Cranial Irradiation Overview Collaborative Group (2002) Cranial irradiation for preventing brain metastasis of small cell lung cancer in patients in complete remission. Cochrane Database Syst Rev 2002: CD000285.
2. Neville A (2004) Lung cancer. Clin Evid 2004: 2031–2055.
3. Arriagada R, Le Chevalier T, Riviere A (2002) Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: Analysis of 505 randomized patients. Ann Oncol 13: 748–754.

Answer 10. Etoposide is associated with reduced survival compared with combination chemotherapy.

Two RCTs in people with extensive-stage small cell lung cancer found that oral etoposide reduced survival compared with combination chemotherapy at one year [1,2].

References
1. Souhami RL, Spiro SG, Rudd RM, Ruiz de Elvira MC, James LE, et al. (1997) Five-day oral etoposide treatment for advanced small cell lung cancer: Randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 89: 577–580.
2. Girling DJ (1996) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348: 563–566.
3. Goss G, Paszat L, Newman T, Evans WK, Browman G (1998) Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small cell lung cancer. Cancer Prev Control 2: 32–39.
4. Guangchuan XU, Rong T, Lin P (2000) Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: A randomized study on 70 patients. Chin Med J 113: 617–620.
5. Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, et al. (2003) A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40: 181–186.
6. Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, et al. (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343: 1217–1222.
7. Winston TL, Livingston R, Johnson D, Rigas J, Cormier Y, et al. (2004) A prospective randomised trial of adjuvant vinorelbin (VIN) and cisplatin (CIS) in completely resected stage II and II non small cell lung cancer (NSCLC) intergroup JBR.10 [abstract]. Proc Am Soc Clin Oncol 2004: abstract number 7018.
8. Strauss GM, Herndon J, Maddaus MA, Johnson EA, et al. (2004) Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of cancer and leukemia group B (CALGB) protocol 9633 [abstract]. Proc Am Soc Clin Oncol 2004: abstract number 7019.

American Thoracic Society/European Respiratory Society (1997) Pre-treatment evaluation of non-small cell lung cancer. Am J Respir Crit Care 156: 320–332.

Arriagada R, Le Chevalier T, Riviere A (2002) Patterns of failure after prophylactic cranial irradiation in small-cell lung cancer: Analysis of 505 randomized patients. Ann Oncol 13: 748–754.

Caraballoso M, Sacristan M, Serra C, Boufill X (2002) Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev 2002: CD001241.

Depierre A, Milleron B, Morno-Sibilot D, Chevret S, Quoix E, et al. (2002) Preoperative chemoradiotherapy followed by surgery compared with curative surgery in resectable stage I (except T1N0), II, and IIIA non-small cell lung cancer. J Clin Oncol 20: 247–253.

Endo C, Saito Y, Iwanami H, Tsushima T, Imai T, et al. (2003) A randomized trial of postoperative UFT therapy in p stage I, II non-small cell lung cancer: North-east Japan Study Group for Lung Cancer Surgery. Lung Cancer 40: 181–186.

Girling DJ (1996) Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 348: 563–566.

Goss G, Paszat L, Newman T, Evans WK, Browman G (1998) Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small cell lung cancer. Cancer Prev Control 2: 32–39.

Guangchuan XU, Rong T, Lin P (2000) Adjuvant chemotherapy following radical surgery for non-small-cell lung cancer: A randomized study on 70 patients. Chin Med J 113: 617–620.

IARC (2004) GLOBOCAN 2002 [database]. Lyon (France): IARC press. Available: http://www-depdb.iarc.fr/globocan/GLOBOframe.htm. Accessed 11 February 2005.

Ihde DC, Pass HI, Glastein E (1997) Lung cancer. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, principles, and practice of oncology, 5th ed. Philadelphia: Lippincott-Raven. pp. 849–959.

Keller SM, Adak S, Wagner H, Herskovic A, Komaki R, et al. (2000) A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer. N Engl J Med 343: 1217–1222.

Winston TL, Livingston R, Johnson D, Rigas J, Cormier Y, et al. (2004) A prospective randomised trial of adjuvant vinorelbin (VIN) and cisplatin (CIS) in completely resected stage II and II non small cell lung cancer (NSCLC) intergroup JBR.10 [abstract]. Proc Am Soc Clin Oncol 2004: abstract number 7018.